Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea

Authors
Category Primary study
ConferenceBlood
Year 2014
This article has no abstract
Epistemonikos ID: 90e8010e3d7c2c9928047486f7f8589809d9d12f
First added on: Apr 28, 2026